 INmune Bio, Inc. INMB the Company, a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced that the Medicines and Healthcare products Regulatory Agency MHRA; the UK equivalent of the FDA has given approval to initiate a Phase I clinical trial of INKmune, a novel therapy to prime the patients own NK cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome MDS EUDRACT 2019-004820-40. This single center Phase I trial will be the first-in-man study using INKmune. Based on the current environment and timetable of its clinical site, INmune Bio is targeting the study initiation in the 2nd half of this year. 